Belite Bio (BLTE) Tax Provisions (2023 - 2026)
Belite Bio (BLTE) posted quarterly Tax Provisions of -$6.0 million for Q3 2024, down 599500.0% year-over-year from N/an in Q4 2023, and down 199.9% quarter-over-quarter from $6.0 million in Q1 2024.
Powered by 
Analysis
Belite Bio (BLTE) Tax Provisions (2023 - 2026) Analysis & Trends
Belite Bio's Tax Provisions history runs 2 years deep, the most recent figure standing at -$6.0 million for Q3 2024.
- In Q3 2024, Tax Provisions fell 599500.0% year-over-year to -$6.0 million; the TTM figure through Dec 2024 stood at $6000.0 (down 99.93% YoY), while the FY2025 annual figure was -$136000.0, down 2366.67% from the prior year.
- Tax Provisions for Q3 2024 stood at -$6.0 million, down from $6.0 million in the prior quarter.
- The five-year high for Tax Provisions was $6.0 million in Q1 2023, with the low at -$6.0 million in Q3 2024.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.87 Bn | 131.01 Bn | 2.84 Bn | 292.00 Mn |
| 2 | Regeneron Pharmaceuticals | 85.57 Bn | 77.57 Bn | 3.93 Bn | 230.90 Mn |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn | -59.00 Mn |
| 4 | Moderna | 58.19 Bn | 53.05 Bn | 52.00 Mn | 15.00 Mn |
| 5 | Revolution Medicines | 44.07 Bn | 44.07 Bn | - | - |
| 6 | BeOne Medicines | 39.99 Bn | 34.89 Bn | 1.53 Bn | 75.45 Mn |
| 7 | Alnylam Pharmaceuticals | 35.38 Bn | 32.07 Bn | 992.69 Mn | 13.31 Mn |
| 8 | Royalty Pharma | 28.42 Bn | 27.58 Bn | - | - |
| 9 | Insmed | 27.41 Bn | 26.25 Bn | 358.27 Mn | 1.90 Mn |
| 10 | Belite Bio | 6.25 Bn | 6.25 Bn | - | 55,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 55,000.00 |
| Mar 31, 2024 | 6,000.00 |
| Dec 31, 2023 | -1,000.00 |
| Sep 30, 2023 | 1,000.00 |
| Jun 30, 2023 | 0.03 |
| Mar 31, 2023 | 6,000.00 |